Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 30fludarabine phosphate 25Cyclosporine 25Busulfan 20Mycophenolic Acid 18Peripheral Blood Stem Cell Transplantation 17Cord Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Whole-Body Irradiation 15Radiotherapy 15Methotrexate 12Methylprednisolone 10Filgrastim 10Cytarabine 8Etoposide 7Tacrolimus 6Melphalan 6sargramostim 5fludarabine 4Thiotepa 4Granulocyte Colony-Stimulating Factor 4Decitabine 4Cyclosporins 4Azacitidine 4merphos 3Transplantation 3Arsenic Trioxide 3bryostatin 1 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × paricalcitol × Classical hematology × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡